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Abstract
Objective To investigate whether population based primary
prevention (risk factor reduction in apparently healthy people)
might be more powerful than current government initiatives
favouring risk factor reduction in patients with coronary heart
disease (CHD) (secondary prevention).
Design, setting, and participants The IMPACT model was
used to synthesise data for England and Wales describing CHD
patient numbers, uptake of specific treatments, trends in major
cardiovascular risk factors, and the mortality benefits of these
specific risk factor changes in healthy people and in CHD
patients.
Results Between 1981 and 2000, CHD mortality rates fell by
54%, resulting in 68 230 fewer deaths in 2000. Overall smoking
prevalence declined by 35% between 1981 and 2000, resulting
in approximately 29 715 (minimum estimate 20 035, maximum
estimate 44 675) fewer deaths attributable to smoking cessation:
approximately 5035 in known CHD patients and approximately
24 680 in healthy people. Population total cholesterol
concentrations fell by 4.2%, resulting in approximately 5770
fewer deaths attributable to dietary changes (1205 in CHD
patients and 4565 in healthy people) plus 2135 fewer deaths
attributable to statin treatment (1990 in CHD patients, 145 in
people without CHD). Mean population blood pressure fell by
7.7%, resulting in approximately 5870 fewer deaths attributable
to secular falls in blood pressure (520 in CHD patients and
5345 in healthy people) plus approximately 1890 fewer deaths
attributable to antihypertensive treatments in people without
CHD. Approximately 45 370 fewer deaths were thus
attributable to reductions in the three major risk factors in the
population: some 36 625 (81%) in people without recognised
CHD and 8745 (19%) in CHD patients.
Conclusions Compared with secondary prevention, primary
prevention achieved a fourfold larger reduction in deaths.
Future CHD policies should prioritise population-wide tobacco
control and healthier diets.
Introduction
Coronary heart disease (CHD) remains the largest cause of
death in the United States, Europe, and Australasia.1 However,
since the 1980s, CHD mortality rates have halved in Britain and
in many industrialised countries.1 Studies in the US, Europe, and
New Zealand consistently suggest that 50-75% of the falls in car-
diac deaths can be attributed to population-wide improvements
in the major risk factors, particularly smoking, cholesterol, and
blood pressure.2–5 Modern cardiological treatments for known
CHD patients, such as thrombolysis, aspirin, angiotensin
converting enzyme inhibitors, statins, and coronary artery bypass
surgery, generally explain the remaining 25-50% of the fall in
mortality.2–5
Risk factor reduction should thus be a central component of
all CHD policies. However, disagreement continues about
whether to prioritise risk factor reduction across the whole
population, explicitly including all apparently healthy people
(primary prevention), or mainly to target CHD patients (second-
ary prevention). Current funding in the US6 and the United
Kingdom clearly favours secondary prevention. This reflects four
perceived limitations of primary prevention as an “evidence
based” intervention. Firstly, a much quoted Cochrane meta-
analysis of 10 intervention studies in primary care that used
counselling or education to modify more than one cardiovascu-
lar risk factor in adults found only modest changes in risk factors
and no effect on mortality.7 Secondly, although confident about
prescribing drugs, some clinicians may feel uncomfortable in a
health promotion role, perhaps lacking the confidence or skills
to influence complex behaviours such as diet or smoking.8
Thirdly, the very long time scales apparently involved may be a
deterrent.9 Fourthly, the numbers needed to treat to prevent one
event are substantial, often fivefold higher than those for target-
ing CHD patients.10
In truth, both primary and secondary prevention interven-
tions are probably necessary to maximise population health.11
Quantifying their relative contributions is clearly important but
is difficult to do with disease registers or population cohorts.12
Researchers have therefore used models to quantify the
potential contribution of risk factor reductions before and after
CHD is diagnosed in an individual. For example, use of the CHD
policy model suggested that approximately 25% of the decline in
CHD deaths in the US between 1980 and 1990 was explained by
primary prevention and slightly more (29%) was explained by
risk factor reductions in patients with CHD.2
A better understanding of the relative contributions of
primary prevention and secondary prevention to the recent falls
in deaths from CHD is clearly essential, in order to inform future
CHD policy options in Britain and elsewhere.10 We have
therefore used the only validated and comprehensive CHD
model available in the UK.4 We analysed the decrease in CHD
mortality in England and Wales between 1981 and 2000 to esti-
mate the proportions attributable to changes in major cardiovas-
cular risk factors in apparently healthy people (primary
prevention) and in patients with CHD (secondary prevention).
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Methods
IMPACT CHD model
The cell based IMPACT CHD mortality model, previously
validated in Scotland,3 New Zealand,5 and Beijing,13 has been
described elsewhere.3 5 14 Briefly, we used the model to synthesise
data for the adult population of England and Wales—35.5
million people aged between 25 and 84—describing numbers of
CHD patients, uptake of specific treatments, trends in major car-
diovascular risk factors in apparently healthy people in popula-
tions and in specific patient groups, and the effectiveness
(mortality benefits) of the reductions in specific risk factors in
people with and without recognised CHD.4
Data sources
Sources of data included national surveys, official statistics, clini-
cal audits, controlled trials, and meta-analyses. These are detailed
on our website.15
Primary prevention: risk factor trends and mortality benefits
in the general population
For risk factor changes, the model uses regression () coefficients
obtained from large meta-analyses, cohort studies, and
MONICA analyses (appendix 10 on website).4 15 Each 
coefficient quantifies the independent relation between popula-
tion change in a specific CHD risk factor (such as smoking, cho-
lesterol, or blood pressure) and the consequent percentage
change in population mortality from CHD. We then estimated
the subsequent reduction in the number of deaths produced by
the decrease in each major risk factor as the product of three
variables: the number of CHD deaths observed in the base year
(1981), the relative reduction in that risk factor, and the  coeffi-
cient, each stratified by age and sex.4 15
To estimate the impact of the population-wide reduction in
cholesterol due to dietary change, we subtracted the estimated
effect of statins for primary prevention from the overall number
of deaths prevented or postponed in the population due to
change in mean cholesterol concentration. We explicitly consid-
ered demographic change by using age and sex specific popula-
tion CHD mortality and CHD patient numbers for 1981 and for
2000.4
Secondary prevention: risk factor trends and mortality
benefits in CHD patients
We then estimated the mortality benefit attributable to
reductions in each major risk factor (smoking, total cholesterol,
and blood pressure) in each group of CHD patients as the
number of deaths prevented or postponed.4 We categorised
CHD patients according to disease groups: acute myocardial inf-
arction, survivors of myocardial infarction, revascularisation
patients, and patients with unstable angina, chronic angina, and
chronic heart failure. We did not consider the impact of changes
in risk factors in patients with an initial acute myocardial infarc-
tion or unstable angina, because both are transient states. To
avoid double counting, we firstly made adjustments for overlaps
between different treatment groups by subtracting the overlap-
ping subgroup from the main group, as detailed in appendix 8
on the website.4 15
We based age and sex specific smoking cessation rates on
local surveys and audits. We initially assumed that age and sex
specific changes in cholesterol attributable to diet and changes in
blood pressure attributable to population secular trends would
mirror the changes seen in the general population.We then used
rigorous sensitivity analyses to test the effect of much smaller
(–50%) and much larger (+50%) changes.
Statins and other treatments
The model aimed to include all medical and surgical treatments
provided in 2000. This included statins as primary prevention (in
people without recognised CHD) and as secondary prevention
(in CHD patients). We calculated the absolute reduction in mor-
tality by using the relative reduction in mortality reported in the
most recent meta-analysis15 applied to the age specific case fatal-
ity rate observed in unselected patient cohorts. The effect of all
other “secondary prevention” drugs (aspirin,  blockers, and
angiotensin converting enzyme inhibitors) has been previously
reported and was explicitly excluded from this analysis.4 We did
not consider over the counter statins, as these only became avail-
able in 2003.
We estimated the number of deaths prevented or postponed
for specific age and sex groups. We used survival benefit over a
one year time interval throughout.
Sensitivity analyses
Because of the uncertainties surrounding some values, we did a
multiway sensitivity analysis using the analysis of extremes
method.16 Illustrative examples are shown in appendix 7 on the
website.15
Apportioning deaths prevented or postponed between
primary and secondary prevention
We then estimated the deaths prevented or postponed in appar-
ently healthy people as the deaths prevented or postponed in the
entire population minus the deaths prevented or postponed in
each CHD patient group. Illustrative examples are given in the
results section.
Results
Fall in CHD mortality between 1981 and 2000
Between 1981 and 2000, age specific CHD mortality in England
and Wales fell by 62% in men and 45% in women aged 25-84.
This resulted in 68 230 fewer deaths in 2000, compared with the
1981 baseline.4
Medical and surgical treatments together prevented or post-
poned approximately 25 805 deaths (minimum estimate 17 110,
maximum estimate 49 040). This represented 42% of the total
decrease in CHD deaths estimated by the model.4
Approximately 58% of the fall in mortality was attributable to
reductions in the risk factors—mainly smoking, cholesterol, and
blood pressure.4 Changes in the three major cardiovascular risk
factors together produced a best estimate of 45 370 (29 570-
76 835) fewer deaths. In contrast, adverse trends in diabetes,
obesity, and physical activity together generated approximately
7645 (5395-10 730) additional deaths.4
Risk factor reductions in the general population and in CHD
patients
Overall smoking prevalence fell by 35% between 1981 and 2000.
This resulted in approximately 29 715 (20 035-44 675) fewer
deaths. Approximately 5035 (17%; 3100-8255) fewer deaths
resulted from smoking cessation in CHD patients, leaving the
remainder—approximately 24 680 (83%; 16 935-36 420)—
attributable to reduced smoking prevalence in “healthy people”
(table 1).
Population total cholesterol concentrations fell by 4.2%
between 1981 and 2000, resulting in approximately 7900 (5285-
16 695) fewer deaths. Approximately 5770 fewer deaths were
attributable to dietary reduction—approximately 1205 (645-
2455) in CHD patients, leaving some 4565 (3290-9650) fewer
deaths attributable to dietary cholesterol reduction in healthy
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people. Approximately 2135 (1350-4590) fewer deaths were
attributable to statin treatments: 1990 (1305-4180) in CHD
patients and 145 (45-410) in healthy people (table 1).
Mean population diastolic blood pressure fell by 7.7%
between 1981 and 2000, resulting in approximately 7755 (4250-
15 465) fewer deaths. Approximately 520 (285-940) fewer deaths
were attributable to the secular fall in blood pressure in CHD
patients, leaving some 5345 (3125-11 740) in healthy people,
and 1890 (840-2785) fewer deaths were attributable to
antihypertensive treatments in around 7.1 million hypertensive
people (table 1).4
All secondary prevention interventions (risk factor reduc-
tions in CHD patients) together accounted for approximately
8745 (5335-15 830) fewer deaths (table 1). This represented 19%
of the total number of 45 370 deaths prevented or postponed by
change in the three major risk factors between 1981 and 2000
(minimum contribution 18.0%, maximum contribution 21.0%).
The remaining reduction in deaths (45 370 minus 8745)
could then be attributed to primary prevention in healthy
people, which thus accounted for approximately 36 625
(24 235-61 005) fewer deaths (table 1). This 36 625 represented
81% of the total mortality decrease of 45 370 deaths prevented
or postponed by change in the three major risk factors between
1981 and 2000 (minimum contribution 53.4%, maximum
contribution 79.3%).
Sensitivity analyses
The relative contribution to the overall decline in CHD deaths
from primary and secondary prevention for each risk factor was
little changed by whether best, minimum, or maximum estimates
were considered (figure ).
Risk factor reduction benefits in specific groups of CHD
patients
In 2000, approximately 30 530 (18 630-54 180) deaths were pre-
vented or postponed in patients with CHD. Some 23 770 (77.9%)
were attributable to medical and surgical treatments, and 6760
(22.1%) were attributable to reductions in the three major risk
factors. Substantial contributions came from three patient
groups: post-myocardial infarction and post-surgical interven-
tion groups, angina in the community, and heart failure (table 2).
Table 1 Fall in coronary heart disease mortality attributable to changes in risk factors in people with and without recognised coronary heart disease: England
and Wales, 1981-2000
Risk factor
Change in
population risk
factor level (%)
Deaths prevented or postponed
Total
Primary prevention* Secondary prevention*
No (min-max)† % No (min-max)† %
Smoking:
Overall −35 24 680 (16 935-36 420) 83 5 035 (3 100-8 255) 17 29 715 (20 035-44 675)
Cholesterol:
Overall −4.2 4 710 (3 335-10 060) 60 3 190 (1 950-6 635) 40 7 900 (5 285-16 695)
Attributable to diet 4 565 (3 290-9 650) 1 205 (645-2 455) 5 770 (3 935-12 105)
Attributable to statins 145 (45-410) 1 990 (1 305-4 180) 2 135 (1 350-4 590)
Blood pressure:
Overall −7.7 7 235 (3 965-14 525) 93 520 (285-940) 7 7 755 (4 250-15 465)
Secular trend 5 345 (3 125-11 740) 520 (285-940) 5 870 (3 410-12 680)
Antihypertensive treatment 1 890 (840-2 785) ‡ 1 890 (875-3 165)
All three major risk factors 36 625 (24 235-61 005) 81 8 745 (5 335-15 830) 19 45 370 (29 570-76 835)
*Primary prevention=in healthy people; secondary prevention=in people with coronary heart disease.
†All numbers rounded to nearest 5; min-max=minimum and maximum estimates.
‡Antihypertensive treatment in coronary heart disease patients was subsumed in secondary prevention medication component of IMPACT model.
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Sensitivity analysis comparing primary and secondary prevention: falls in coronary heart disease mortality attributable to changes in risk factors in people with and
without recognised coronary heart disease in England and Wales, 1981-2000 (best estimate, with minimum and maximum estimates). CHD=coronary heart disease
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Approximately 1990 (1305-4180) fewer deaths were attribut-
able to statin treatments in CHD patients. The biggest contribu-
tions came from statin treatment for patients after acute
myocardial infarction (460), revascularisation (675), or heart fail-
ure (750) (table 2).
Risk factor reduction benefits by age and sex
Of the 45 370 (29 570-76 835) deaths prevented or postponed
by reductions in risk factors, 73.7% occurred in men and 26.3%
in women (table 3). The relative contribution from secondary
prevention was consistently higher in women (27.3%) than in
men (16.4%). The contribution from secondary prevention was
relatively consistent across age groups in men, but in women this
contribution was higher in the youngest and oldest groups than
in those in between (table 3).
Discussion
Impact of primary compared with secondary prevention
Mortality from coronary heart disease in England and Wales fell
by 54% between 1981 and 2000.1 4 Approximately half of this
large fall could be attributed to primary prevention, defined as
reductions in the three major risk factors in people without rec-
ognised CHD. Furthermore, primary prevention had a fourfold
greater impact than secondary prevention (risk factor reductions
in CHD patients). This was much as predicted by Rose and oth-
ers.11 12 The fourfold advantage apparently contrasted with the
25% to 29% split estimated by using the CHD policy model for
the US population 1980-90.2 However, the difference may
substantially reflect a different categorisation of primary versus
secondary prevention rather than true differences between
populations.
The fourfold advantage of primary prevention becomes
12-fold greater when life years gained are considered, rather
than simply deaths postponed.14 We have previously shown that
a death prevented or postponed in a patient with recognised
CHD gained an additional 7.5 years of life, on average. In
contrast, each death prevented or postponed by primary preven-
tion gained an additional 21 years of life, on average.14
Contributions of individual risk factors
The biggest single contribution reflected a large decrease in
overall smoking prevalence, from 39% in 1981 to 28% in 2000.4
This resulted in approximately 29 715 fewer deaths, of which
83% were in “healthy people” and 17% resulted from smoking
cessation in CHD patients. The evidence base is now particularly
solid for smoking cessation, with 50 year data from the Doll
cohort and the recent Cochrane meta-analysis showing a 36%
reduction in mortality in CHD patients who stop smoking.17 18
However, opportunities for smoking cessation in secondary pre-
vention are frustratingly limited, as around 50% of myocardial
infarctions are rapidly fatal.19 It therefore makes sense to
energetically target smokers before they develop clinical disease.
In Britain, substantial resources are now being spent on smoking
cessation services, and four week results look promising.
However, there is no room for complacency; subsequent relapse
is common, and only a minority of all smokers have yet been
reached. Furthermore, although the recent advertising ban is
welcome, further tobacco control measures must be imple-
mented.
Primary prevention also had an almost fourfold bigger
impact on mortality than did secondary prevention for dietary
based cholesterol reduction (some 4565 fewer deaths in healthy
people compared with 1205 in CHD patients) and a 10-fold big-
ger impact through blood pressure reduction (5345 fewer deaths
in healthy people compared with 520 in patients with CHD).
Antihypertensive treatments contributed somewhat fewer
deaths—only about 1890.
UK population levels of both cholesterol and blood pressure
declined modestly between 1981 and 2000. The factors underly-
ing these falls are clearly complex. Having explicitly considered
Table 2 Fall in coronary heart disease mortality in England and Wales
between 1981 and 2000: numbers of deaths prevented or postponed by
treatments and by changes in risk factors in people with coronary heart
disease, categorised into specific groups
Patient groups
No of deaths
prevented or
postponed*
Minimum and
maximum
estimates Percentage
After acute myocardial infarction
All treatments: 3 840 2 865-5 080 66.5
Statins 460 430-1 340 8.0†
Smoking cessation 1 450 880-2 315 25.1
Cholesterol reduction (diet) 335 250-560 5.8
Blood pressure reduction 140 70-230 2.4
Total 5 765 4 060-8 185 100
After CABG surgery or angioplasty
All treatments: 3 055 1 740-7 620 74.0
Statins 675 380-1 495 16.3†
Smoking cessation 820 510-1 150 19.8
Cholesterol reduction (diet) 195 65-320 4.7
Blood pressure reduction 60 40-130 1.4
Total 4 130 2 355-9 225 100
Angina
Revascularisation 2 320 1 185-3 495 100
Chronic angina in the community
All treatments: 1 105 720-2 395 43.6
Statins 105 95-275 4.2†
Smoking cessation 1 115 715-1 605 44.0
Cholesterol reduction (diet) 200 95-460 7.5
Blood pressure reduction 115 75-170 4.5
Total 2 535 1 605-4 630 100
Acute myocardial infarction
All treatments 4 780 3 225-8 290 100
Unstable angina
All treatments 910 620-1 620 100
Heart failure requiring hospital admission
All treatments: 4 535 2 295-7 680 85.2
Statins 415 290-575 7.7†
Smoking cessation 595 400-1 025 11.2
Cholesterol reduction (diet) 130 55-265 2.5
Blood pressure reduction 60 15-97 1.2
Total 5 325 2 765-9 070 100
Heart failure in the community
All treatments: 3 220 1 950-6 345 67.6
Statins 335 110-490 7.0†
Smoking cessation 1 055 600-2 160 22.1
Cholesterol reduction (diet) 350 175-845 7.3
Blood pressure reduction 140 85-310 3.0
Total 4 770 2 810-9 665 100
All groups
All treatments: 23 770‡ 14 600-42 530 77.9
Statins 1 990 1 305-4 180 6.5†
Smoking cessation 5 035 3 100-8 255 16.5
Cholesterol reduction (diet) 1 205 645-2 455 3.9
Blood pressure reduction 520 285-940 1.7
Total 30 530 18 630-54 180 100
CABG=coronary artery bypass graft.
*All numbers rounded to nearest 5, so sums may differ from totals in table 1.
†Statin percentages already included within treatments.
‡This total mirrors the treatment effect (25 805) reported in our previous publication,15 which
included antihypertensive treatment in people without coronary heart disease (1888) and
statin treatment as primary prevention (145).
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therapeutic interventions in our model, we then attributed the
remainder of the cholesterol and blood pressure declines to life-
style changes; this could be either physical activity or diet.
Because the proportion of people who were moderately physical
active probably decreased slightly,4 these falls in cholesterol con-
centrations might reasonably be cautiously attributed to the well
documented positive trends in dietary intake of fruit, fibre, and
unsaturated fats.1 Reduced saturated fat and salt intake will both
have benefited population blood pressure.1 20
Effectiveness of population approach
Substantial and sustained change in dietary habits is hard to
achieve in individuals.21 In contrast, substantial 0.5-1.0 mmol/l
falls in average total cholesterol have been reported in entire
populations in Finland and Mauritius.22 23 These almost certainly
reflect a combination of factors: policy, finance, health
promotion, and multisectoral collaboration, as well as advice to
individuals.22 23
These findings support the population prevention
approach.11 It has been repeatedly shown that achieving
apparently small mortality benefits across the entire population
would produce far larger overall gains than merely targeting
people at high risk in order to achieve big reductions in mortal-
ity in a relatively small number of people.11 12
The international evidence is also increasingly powerful. The
most effective and cost effective interventions to reduce major
risk factors have come from comprehensive cardiovascular strat-
egies underpinned by robust national policies, as in Finland,
Mauritius, and Singapore.1 7 The US has promoted an
increasingly cholesterol conscious culture, with clear gains. Many
American states now have complete public bans on smoking.24
Ireland has followed this very successfully. Smoke-free cam-
paigns in Liverpool, Birmingham, London, and Scotland are all
gaining momentum, with further support from the recent public
health white paper, which also proposes legislation to reduce
saturated fat and salt in processed food.20
Strengths and limitations of modelling studies
Modelling studies have several potential strengths. They can
transparently integrate and simultaneously consider huge
amounts of data from many sources. Explicit assumptions can
then be tested by using sensitivity analyses. Modelling studies
also have limitations. They are dependent on the variable quality
and extent of data available on CHD risk factor trends and treat-
ment uptakes. Rigorous sensitivity analyses are therefore
essential.16 However, for each risk factor, the relative contribution
of primary and secondary prevention to the overall decline in
CHD deaths was reasonably consistent whether considering
best, minimum, or maximum estimates (figure ). Finally, lag times
may be relatively unimportant over two decades. Substantial
mortality reductions occur within one or two years of reducing
cholesterol or stopping smoking.18
Contribution of statin treatment
Approximately 1990 fewer deaths were attributable to statin
treatment in CHD patients, and 145 to statins as primary
prevention. This estimate is less than the recently quoted UK
government figure of “7000 lives saved by statins in 2003.”10
However, although hospital discharge prescribing may be
increasing, realistic assumptions about long term prescribing
and compliance are essential.
Conclusions
Approximately half the recent large falls in CHD deaths in Eng-
land and Wales can be attributed to primary prevention:
reductions in the three major risk factors in people without rec-
ognised CHD. Much as predicted, primary prevention had a
fourfold bigger impact on mortality than did secondary preven-
tion. These findings might be cautiously generalisable to other
comparable industrialised countries. Comprehensive CHD strat-
egies should therefore focus on primary prevention, particularly
tobacco control and healthier diets.
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What is already known on this topic
Coronary heart disease (CHD) mortality has halved since
1981 in the UK, resulting in 68 230 fewer deaths in 2000
Current government initiatives favour risk factor reduction
in CHD patients (secondary prevention), but population
based primary prevention (risk factor reduction in
apparently healthy people) might be more powerful
What this paper adds
Approximately 45 370 fewer CHD deaths were attributable
to reductions in smoking, cholesterol, and blood pressure in
the whole population
Some 36 625 (81%) of these fewer deaths occurred in
people without recognised CHD and 8745 (19%) in CHD
patients
Compared with secondary prevention, primary prevention
achieved a fourfold larger reduction in deaths
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